Biogen Idec Receives Director Nomination Proposal

Monday, January 28, 2008 7:00 am EST

Dateline:

CAMBRIDGE, Mass.

Public Company Information:

NASDAQ:
BIIB

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) today announced that it has received notice from Icahn Partners LP and certain of its affiliates for the nomination of three individuals, Alexander J. Denner, Richard C. Mulligan and Anne B. Young, to Biogen Idecs Board of Directors at the Companys 2008 Annual Meeting.

The notice also includes a proposal to amend the Companys bylaws to set the size of the Board at 12.

Biogen Idecs Board said it will review the notice and consider it in light of the best interests of all shareholders of the Company.

About Biogen Idec

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec's significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid arthritis. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.

Important Information

Biogen Idec and its directors, executive officers and other members of its management and employees may be deemed to be participants in the solicitation of proxies from the stockholders of Biogen Idec in connection with the Companys 2008 annual meeting of stockholders. Information concerning the interests of participants in the solicitation of proxies will be included in any proxy statement filed by Biogen Idec in connection with the Companys 2008 annual meeting of stockholders.

In addition, Biogen Idec files annual, quarterly and special reports with the Securities and Exchange Commission (the SEC). The proxy statements and other reports, when available, can be obtained free of charge at the SECs web site at www.sec.gov or from Biogen Idec at www.biogenidec.com. Biogen Idec stockholders are advised to read carefully any proxy statement filed in connection with the Companys 2008 annual meeting of stockholders when it becomes available before making any voting or investment decision. The Companys proxy statement will also be available for free by writing to Biogen Idec Inc., 14 Cambridge Center, Cambridge, MA 02142. In addition, copies of the proxy materials may be requested from our proxy solicitor, Innisfree M&A Incorporated, by toll-free telephone at (877) 750-5836 or by e-mail at info@innisfreema.com.

Contact:

Biogen Idec
Media:
Director, Public Affairs
Naomi Aoki, 617-914-6524
or
Investor Relations:
Director, Investor Relations
Keith Regnante, 617-679-2812